XSpray Pharma AB (STU:6XP) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6XP XSpray Pharma AB STU:6XP
30 GF Score
Price €0.92
View Full Analysis

What is XSpray Pharma AB Net Loan?

Net Loan only applies to banks and insurance companies.

STU:6XP
30GF Score
XSpray Pharma AB STU:6XP
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XSpray Pharma AB Business Description

Other Exchanges XSPRAY:Sweden0GHZ:UK
Address Scheeles vag 2, Solna, SWE, SE-171 65
XSpray Pharma AB is a pharmaceutical company focused on developing improved PKIs for cancer treatment, leveraging its proprietary HyNap technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Its product portfolio includes Dasynoc and other product candidates in different stages of development such as XS003 nilotinib, XS008 axitinib, and other.
30GF Score

Get the complete analysis for STU:6XP

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.92
Price